Vor Biopharma Inc.

VOR

US9290332074

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:28:09 12/02/2026 pm IST			5-day change	1st Jan Change
12.77 ^USD	-4.27%		+5.30%	-2.83%

09/02	6,282,297 Common Stock of Vor Biopharma Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2026.	CI
09/02	Certain Warrants of Vor Biopharma Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2026.	CI

North American Morning Briefing : Stock Futures -2-

Published on 07/01/2025 at 03:53 pm IST

Dow Jones

VOR BIOPHARMA INC.

-4.27%

ORACLE CORPORATION

-1.89%

WALT DISNEY COMPANY (THE)

-5.85%

WHIRLPOOL CORPORATION

-0.82%

WHIRLPOOL S.A.

+0.43%

CorMedix Cut to Hold From Buy by D. Boral Capital

Disney Raised to Buy From Hold by Jefferies

Oracle Raised to Buy From Hold by Stifel

ProKidney Cut to Underperform From Neutral by B of A Securities

Vor Biopharma Raised to Buy From Neutral by HC Wainwright & Co.

Whirlpool Raised to Buy From Neutral by Longbow Research

This article is a text version of a Wall Street Journal newsletter published earlier today.

(END) Dow Jones Newswires

07-01-25 0622ET

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
VOR BIOPHARMA INC.	12.77USD	-4.27%	+5.30%	55Cr
ORACLE CORPORATION	154.18USD	-1.89%	+12.50%	45TCr
WALT DISNEY COMPANY (THE)	101.79USD	-5.85%	-3.42%	19TCr
WHIRLPOOL CORPORATION	92.06USD	-0.82%	+9.01%	521.17Cr
WHIRLPOOL S.A.	4.660BRL	+0.43%	-0.64%	129.27Cr

Latest news about Vor Biopharma Inc.

09/02	6,282,297 Common Stock of Vor Biopharma Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2026.	CI
09/02	Certain Warrants of Vor Biopharma Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2026.	CI
09/02	Certain Units of Vor Biopharma Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2026.	CI
09/02	Certain Stock Options of Vor Biopharma Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2026.	CI
03/01	Vor Biopharma Inc. Announces Separation of Qing Zuraw as Chief Development Officer, Effective December 31, 2025	CI
24/12	Vor Biopharma Inc Announces Board Appointments, Effective December 18, 2025	CI
22/12	Vor Biopharma Inc.(NasdaqGS:VOR) added to NASDAQ Biotechnology Index	CI
19/12	Vor Biopharma Inc. Announces Resignation of Sarah Reed as to the Board, Effective December 17, 2025	CI
17/12	TD Cowen Initiates Vor Biopharma at Buy	MT
15/12	Vor Biopharma Launches $150 Million Private Placement; Shares Rise	MT
15/12	Vor Bio announces $150 million private placement	RE
09/12	JPMorgan Initiates Vor Biopharma at Overweight With $43 Price Target	MT
09/12	Top Premarket Gainers	MT
25/11	Wedbush Boosts Price Target on Vor Biopharma to $9 From $0.40, Keeps Neutral Rating	MT
14/11	Vor Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/11	Top Midday Decliners	MT
11/11	Top Premarket Decliners	MT
11/11	Vor Biopharma Prices $100 Million Common Stock Offering; Shares Down Pre-Bell	MT
11/11	Vor Bio prices public offering of 10 million shares at $10 each	RE
08/11	Vor Biopharma Inc. Achieves Primary Endpoint of Reducing Proteinuria in Stage A of A Phase 3 Clinical Study for Iga Nephropathy in China	CI
08/11	Vor Biopharma says primary endpoint achieved in phase 3 clinical study evaluating Telitacicept	RE
03/11	Vor Bio Appoints Jeremy Sokolove as Chief Medical Officer	CI
29/25/29	Vor Biopharma Says Telitacicept Sustains Efficacy in Phase 3 Myasthenia Gravis Trial in China	MT
29/25/29	Vor Biopharma says 100% patients on Telitacicept achieve >=2-point MG-ADL improvement	RE
17/25/17	Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025	CI

Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Companyâ€™s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.

Employees

154

Sector

Biotechnology & Medical Research

Calendar

19/03 - Q4 2025 Earnings Release (Projected)

More about the company